P

resident Trump’s proposed budget for 2018, rife with deep cuts including a 20 percent funding reduction for the National Institutes of Health, has been greeted with a chorus of dismay from biopharma scientists and executives.

Talia Bronshtein/STAT Source: GPO: Budget of the United States Government

Consider the words used by industry veterans interviewed by STAT: “Pretty horrifying.” “A tragedy.” “Appalling.” “Incredibly short-sighted.” (One exception was the drug industry’s top lobbying group PhRMA, which put out a statement that … didn’t say much of anything.)

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy